Beyond the Cliff: How Generic Drug Makers Can Forge Value and Market Exclusivity with the 505(b)(2) Pathway
In the relentless world of pharmaceuticals, the generic drug industry stands as a titan of volume and a cornerstone of […]
October 2018
The 505(b)(2) Pathway: Unlocking a Hybrid Strategy for Drug Innovation
In the relentless and high-stakes world of pharmaceutical development, the path from molecule to market is fraught with peril. On
The 505(b)(2) Pathway: Unlocking a Hybrid Strategy for Drug Innovation Read Post »
Pharmaceutical Portfolio Management: The Definitive Technical Guide for IP Teams, R&D Leads, and Institutional Investors
1. What Pharmaceutical Portfolio Management Actually Is (and What Most Teams Get Wrong) Pharmaceutical portfolio management is the discipline of
Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection
I. Executive Summary Follow-on pharmaceutical innovations represent a critical, often underestimated, dimension of medical progress. These advancements, which build upon
Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection Read Post »
